flow study semaglutide FLOW- the Visual Abstract — NephJC Diabetes Distilled: Keeping kidneys FLOWing

GLP-1 receptor agonists like semaglutide have transformed weight loss outcomes for millions of patients, with clinical trials showing average weight reductions of 1522% of baseline body weight

The wide use of these drugs and their adverse effects, although rare, need to be considered and calculated by patients who are using the drugs for weight

Note that upper arm injections are generally recommended to be administered by a caregiver, per manufacturer instructions for use

So while there is a long road ahead with plenty of potential land mines along the way, this health researcher is cautiously optimistic about the promise of these new tools to help our metabolic and cardiovascular health

Like many others, these typically follow a controversies conference - in this case one from 2015 (Perkovic et al, Kidney Int 2016)